Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.85 USD | +8.84% | +11.18% | -15.22% |
Jun. 03 | Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate | MT |
Jun. 03 | Transcript : Intellia Therapeutics, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.22% | 2.29B | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy